Abstract
ABSTRACT
To investigate the epidemiology associated with genetic types and macrolide resistance of
Mycoplasma pneumoniae
(MP) in children during and post-COVID-19 in Baoding. A retrospective analysis was conducted on 13,534 children and adolescents (≤18 years old) with community-acquired pneumonia from January 2022 to December 2024. MP detection and macrolide resistance-associated mutation analysis were performed using multiplex real-time PCR. Multilocus variable-number tandem-repeat analysis (MLVA) was used for genotyping.
Mycoplasma pneumoniae
pneumonia (MPP) cases rose significantly from 844 (2022) to 6,346 (2024) (
P
P
P
IMPORTANCE
Understanding the epidemiological characteristics of
Mycoplasma pneumoniae
(MP) is essential for effective management of
Mycoplasma pneumoniae
pneumonia (MPP). This study examines the epidemiology associated with genetic types and macrolide resistance of MP in children with MPP in Baoding, China, during and after the lifting of non-pharmaceutical interventions (NPIs). Data from 9,728 children diagnosed with MPP from January 2022 to December 2024 were analyzed. MPP cases rose significantly from 844 in 2022 to 6,346 in 2024, while the overall prevalence of macrolide-resistant MP was 95.92%. Notably, a striking genotype shift from M3562 (77.10%/2022–33.13%/2024) to M4572 (15.74%/2022–56.72%/2024) was observed over this period. Severe MPP proportion was significantly higher in patients with M3562 (20.63%) infection than that with M4572 (13.97%). This research underscores the urgent need for strengthened surveillance, rational antibiotic use, and targeted prevention strategies to address MP infections in the post-pandemic period.